Takeda Pharmaceutical Co. Chief Executive Officer Christophe Weber pushed back against dissident shareholders seeking to stop the drugmaker's acquisition of Shire PLC, saying he won't release minutes of boardroom discussions.
A group including members of Takeda's founding family opposes the planned $62 billion (about ¥7 trillion) acquisition of the U.K.-listed biotech, which would rank as the biggest overseas acquisition ever by a Japanese company.
The investors plan to sue Takeda in a bid to obtain details of the board talks leading up to the May deal, trade publication DealReporter said last week.